Efficacy of secukinumab in patients with hidradenitis suppurativa based on the international hidradenitis suppurativa severity scoring system (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

被引：0

作者：

Zouboulis, Christos C. ^{[1
,2
,3
,4
,5
,6
]}

Kyrgidis, Athanassios ^{[1
,7
]}

Alavi, Afsaneh ^{[1
,8
]}

Jemec, Gregor B. E. ^{[1
,9
]}

Martorell, Antonio ^{[1
,10
]}

Marzano, Angelo V. ^{[11
,12
]}

van der Zee, Hessel H. ^{[1
,13
]}

Muscianisi, Elisa ^{[14
]}

Kasparek, Torben ^{[15
]}

Bachhuber, Teresa ^{[16
]}

Wozniak, Magdalena B. ^{[16
]}

Ortmann, Christine-Elke ^{[15
]}

Lobach, Iryna ^{[15
]}

Ravichandran, Shoba ^{[14
]}

Tzellos, Thrasyvoulos ^{[1
,17
]}

机构：

[1] European Hidradenitis Suppurativa Fdn EHSF, Dessau, Germany

[2] Brandenburg Med Sch Theodor Fontane, Dessau, Germany

[3] Staedt Klinikum Dssau, Fac Hlth Sci Brandenburg, Dept Dermatol, Dessau, Germany

[4] Staedt Klinikum Dssau, Fac Hlth Sci Brandenburg, Dept Venereol, Dessau, Germany

[5] Staedt Klinikum Dssau, Fac Hlth Sci Brandenburg, Dept Allergol, Dessau, Germany

[6] Staedt Klinikum Dssau, Fac Hlth Sci Brandenburg, Dept Immunol, Dessau, Germany

[7] Aristotle Univ Thessaloniki, Papanikolaou Gen Hosp Thessaloniki, Dept Maxillofacial Surg, Thessaloniki, Greece

[8] Mayo Clin, Dept Dermatol, Rochester, MN USA

[9] Univ Copenhagen, Zealand Univ Hosp, Roskilde & Hlth Sci Fac, Dept Dermatol, Copenhagen, Denmark

[10] Hosp Manises, Dept Dermatol, Valencia, Spain

[11] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[12] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[13] Erasmus MC, Dept Dermatol, Rotterdam, Netherlands

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Novartis Ireland Ltd, Dublin, Ireland

[17] Nordland Hosp Trust, Dept Dermatol, Bodo, Norway

来源：

EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：27 / 28

页数：2

共 4 条

[1] ClinicalTrials.gov, identifier: NCT05322473.
[2] HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study
Kimball, A. B.
Sobell, J. M.
Zouboulis, C. C.
Gu, Y.
Williams, D. A.
Sundaram, M.
Teixeira, H. D.
Jemec, G. B. E.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (06) : 989 - 994
[3] Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa
Tzellos, Thrasivoulos
van Straalen, Kelsey R.
Kyrgidis, Athanassios
Alavi, Afsaneh
Goldfarb, Noah
Gulliver, Wayne
Jemec, Gregor B. E.
Lowes, Michelle A.
Marzano, Angelo Valerio
Prens, Errol P.
Sayed, Christopher J.
van der Zee, Hessel H.
Zouboulis, Christos C.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (02) : 395 - 401
[4] Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
Zouboulis, C. C.
Tzellos, T.
Kyrgidis, A.
Jemec, G. B. E.
Bechara, F. G.
Giamarellos-Bourboulis, E. J.
Ingram, J. R.
Kanni, T.
Karagiannidis, I.
Martorell, A.
Matusiak, L.
Pinter, A.
Prens, E. P.
Presser, D.
Schneider-Burrus, S.
von Stebut, E.
Szepietowski, J. C.
van der Zee, H. H.
Wilden, S. M.
Sabat, R.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : 1401 - 1409

← 1 →